Cargando…
The Dark Side of the COVID-19 Treatments on Mycobacterium Tuberculosis Infection
Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at the end of 2019, a number of medications have been used to treat the infection and the related Coronavirus disease – 19 (COVID-19). Some of the administered drugs were tested or used in practice only on the basis...
Autores principales: | De Maio, Flavio, Bianco, Delia Mercedes, Delogu, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992620/ https://www.ncbi.nlm.nih.gov/pubmed/35444762 http://dx.doi.org/10.4084/MJHID.2022.021 |
Ejemplares similares
-
Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using In Vitro Models of Infection
por: Bianco, Delia Mercedes, et al.
Publicado: (2023) -
Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection
por: Chiacchio, Teresa, et al.
Publicado: (2017) -
The Biology of Mycobacterium Tuberculosis Infection
por: Delogu, Giovanni, et al.
Publicado: (2013) -
PE_PGRS proteins of Mycobacterium tuberculosis: A specialized molecular task force at the forefront of host–pathogen interaction
por: De Maio, Flavio, et al.
Publicado: (2020) -
Evaluation of the Toxic Activity of the Graphene Oxide in the Ex Vivo Model of Human PBMC Infection with Mycobacterium tuberculosis
por: Salustri, Alessandro, et al.
Publicado: (2023)